KBP-5074 is a third-generation non-steroidal mineralocorticoid receptor antagonist (MRA) with a unique pharmacokinetic (PK) profile characterized by a longer half-life and increased mineralocorticoid receptor (MR) affinity than current MRAs.

MRAs can control blood pressure (BP), as well as provide cardiorenal protection by reducing urine albumin/creatinine ratio (UACR) in CKD patients.

CKD, CVD and diabetes patients are at greater risk for hyperkalemia (elevated potassium in the blood), an electrolyte abnormality that can cause muscle weakness, paralysis, cardiac arrhythmias, and sudden cardiac death. Renin-angiotensin-aldosterone system (RAAS) inhibitors, a group of drugs that includes MRAs, are known to further increase the risk of hyperkalemia. 

Based on clinical studies conducted to-date, we believe that KBP-5074 exhibits favorable efficacy (UACR / BP reductions), as well as improved tolerability (reduced hyperkalemia and proteinuria) when compared to currently approved MRAs. 

KBP-5074 is currently evaluating patients in a global Phase 2b study evaluating its ability to treat uncontrolled hypertension and cardiorenal disease in stage 3b/4 Chronic Kidney Disease (CKD) patients who are at high risk of hyperkalemia and for whom existing MRAs are contraindicated. Top-line data from this study has been reported in the second half of 2020. 

Based on its well-characterized mechanism of action and potentially superior safety, KBP-5074 may have therapeutic value in additional indications, including advanced CKD, Heart Failure (HF) in advanced CKD patients, HF in Dialysis patients and Heart failure with preserved ejection fraction (HFpEF).